The information on this page is not country-specific and may contain information that is outside the licensing conditions in your country. Please always refer to the prescribing information approved in your country.
PROOF Study Quality-of-Life results
Improvements in physical HRQoL1,2
Reduced annual bleed rates (ABRs) led to improvements in physical HRQoL among haemophilia patients with inhibitors.1,2 Patients on FEIBA prophylaxis showed a trend toward improvements in HRQoL versus those who received on-demand treatment, but this trend was not statistically significant.1,2*†
- After 12 months of follow-up, patients on prophylaxis reported a mean improvement of 0.08 on the EQ-5D index score and 15.7 on the EQ-5D VAS, both larger than the established minimal important difference (MID) for these measures (0.07 and 7, respectively).1,2
Learn about the PROOF Study design>>
Trend toward improved function and overall HRQoL1,2
The EQ-5D health profile showed the following trends† in percentage of prophylaxis patients reporting improved function when compared with the on-demand patients: mobility (17% vs. 6%), self-care (25% vs. 6%), and usual activities (25% vs. 12%), anxiety/depression (31% vs. 33%), and pain/comfort (19% vs. 17%).1,2†
- With regard to Haem-A-QoL, prophylaxis patients reported improvement in physical health-related quality of life (HRQoL) (21.9) and overall HRQoL (9.5), which was larger than the estimated MID thresholds (11.4 and 7.7, respectively)(ns).1,2†
Notations
ns=not significant
* The relatively small sample size limited the ability to detect significant differences in improvements between on-demand and prophylaxis groups.
† Not significant
‡ 12 months
§ When controlling for age and time.
References
- 1. Antunes SV, Tangada S, Stasyshyn O, et al. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors [published online ahead of print August 1, 2013]. Haemophilia. 2014;20(1):65-72. DOI:10.1111/hae.12246.
- 2. Stasyshyn O, Antunes SV, Mamanov V, et al. Health-related quality of life in hemophilia patients with inhibitors receiving prophylaxis with anti-inhibitor coagulant complex (AICC): results from AICC Prophylaxis Study. Abstract presented at: XXIV Congress of the International Society on Thrombosis and Haemostasis; June 29-July 4, 2013; Amsterdam, the Netherlands.
The results are in
In the Pro-FEIBA study (n=26), FEIBA prophylaxis showed a significant reduction in the frequency of bleeding events in severe haemophilia A patients with FVIII inhibitors Read more
Publications
Visit Haemophilia to read the PROOF Study and access to more articles related to managing haemophilia patients with inhibitors. Read more
Sustained activity
FEIBA offers a long dosing interval. Read more
Demonstrated efficacy in prophylaxis
Learn how FEIBA prophylaxis can reduce bleed frequency and preserve joints. Read more
Dosing FEIBA
Learn how to dose FEIBA. Read more
This is an international site for FEIBA and is intended for Healthcare Providers outside the U.S. The information on this site is not country-specific and may contain information that is outside the licensing conditions in the specific country in which you live. Therefore, please always refer to the prescribing information approved in your country and use the product in line with the approved local prescribing information.